Keratitis - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratitis - Pipeline Review, H2 2016, provides an overview of the Keratitis (Ophthalmology) pipeline landscape.

Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision and sensitivity to light. Risk factors include virus infections, injury, climatic condition and reduced immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively for Keratitis.

Keratitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratitis (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Keratitis Overview 7
Therapeutics Development 8
Pipeline Products for Keratitis - Overview 8
Pipeline Products for Keratitis - Comparative Analysis 9
Keratitis - Therapeutics under Development by Companies 10
Keratitis - Therapeutics under Investigation by Universities/Institutes 11
Keratitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Keratitis - Products under Development by Companies 15
Keratitis - Products under Investigation by Universities/Institutes 16
Keratitis - Companies Involved in Therapeutics Development 17
Adamis Pharmaceuticals Corporation 17
Dompe Farmaceutici S.p.A. 18
NanoViricides, Inc. 19
ReceptoPharm, Inc. 20
RegeneRx Biopharmaceuticals, Inc. 21
SIFI S.p.A 22
The Medicines Company 23
Keratitis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
acyclovir sodium - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
B-2088 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
C-31G - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
dipyridamole - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Herpecide - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
IBN-1 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
JDE-004 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
PIM-45 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
polihexanide - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
RGN-259 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
RPI-MN - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule for Neurotrophic Keratitis - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit ATM for Herpes Keratitis - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
targocil - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
tigecycline - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Keratitis - Dormant Projects 60
Keratitis - Discontinued Products 61
Keratitis - Product Development Milestones 62
Featured News & Press Releases 62
Jun 01, 2016: RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China 62
May 27, 2016: SIFI announces the conclusion of Phase I clinical trial for the development of PHMB an orphan drug for the treatment of Acanthamoeba Keratitis, a rare ocular disease 62
Jan 12, 2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday 63
Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency 63
Oct 21, 2015: RegeneRx Updates on U.S. Ophthalmic Clinical Trials 64
Sep 30, 2015: RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial 64
Sep 21, 2015: RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy Clinical Trial with RGN-259 65
Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy 65
Sep 25, 2014: EuCornea: Dompe wins the "Best Poster Award" for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis 66
Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 67
Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for Keratitis, H2 2016 8
Number of Products under Development for Keratitis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Keratitis - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 17
Keratitis - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 18
Keratitis - Pipeline by NanoViricides, Inc., H2 2016 19
Keratitis - Pipeline by ReceptoPharm, Inc., H2 2016 20
Keratitis - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016 21
Keratitis - Pipeline by SIFI S.p.A, H2 2016 22
Keratitis - Pipeline by The Medicines Company, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Keratitis - Dormant Projects, H2 2016 60
Keratitis - Discontinued Products, H2 2016 61